Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals following the failure of the Phase-3 CARDIO-TTransform trial for Wainua, a treatment for amyloid cardiomyopathy developed with AstraZeneca. Ionis disclosed on July 9, 2026, that the trial did not meet its primary endpoint, leading to a 23.9% drop in its stock price. The investigation focuses on whether Ionis and its officers engaged in securities fraud or other unlawful practices. Investors affected by the stock drop are encouraged to contact Pomerantz LLP for potential class action participation.
The Invesco S&P 500 Equal Weight Consumer Discretionary ETF (RSPD) is rated as a Hold due to its weaker growth prospects and risk-adjusted returns compared to the traditional market-weighted IVV ETF. Despite a higher earnings yield, RSPD's equal weig...
A wallet suspected to belong to the BANK Foundation reportedly transferred 84 million BANK tokens to an entity called Aster. However, the wallet's ownership and the transaction details have not been independently verified, and no on-chain records or ...
The T. Rowe Price Capital Appreciation Equity ETF (TCAF), launched in June 2023, has attracted over $5.5 billion by offering a concentrated portfolio of about 100 high-quality large-cap stocks with a low fee of 0.31%. While it slightly lags the S&P 5...
Vlad.fun, the memecoin launchpad on Robinhood Chain, has halted its operations after uncovering a serious internal integrity issue involving its own team members. This suspension highlights potential risks within crypto project teams and raises conce...
Samsung Electronics America (SEA) has cut around 839 jobs mainly in New Jersey and Texas as it moves its consumer electronics headquarters from Englewood Cliffs, New Jersey, to Plano, Texas. The layoffs affect roles in display, phone, and other consu...
